Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China; Tianjin General Surgery Institute, Tianjin Medical University General Hospital, Tianjin, China.
Department of Vascular Surgery, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, China.
Cytokine. 2024 Jul;179:156598. doi: 10.1016/j.cyto.2024.156598. Epub 2024 Apr 8.
Allograft rejection remains a major obstacle to long-term graft survival. Although previous studies have demonstrated that IL-37 exhibited significant immunomodulatory effects in various diseases, research on its role in solid organ transplantation has not been fully elucidated. In this study, the therapeutic effect of recombinant human IL-37 (rhIL-37) was evaluated in a mouse cardiac allotransplantation model.
The C57BL/6 recipients mouse receiving BALB/c donor hearts were treated with rhIL-37. Graft pathological and immunohistology changes, immune cell populations, and cytokine profiles were analyzed on postoperative day (POD) 7. The proliferative capacities of Th1, Th17, and Treg subpopulations were assessed in vitro. Furthermore, the role of the p-mTOR pathway in rhIL-37-induced CD4 cell inhibition was also elucidated.
Compared to untreated groups, treatment of rhIL-37 achieved long-term cardiac allograft survival and effectively alleviated allograft rejection indicated by markedly reduced infiltration of CD4 and CD11c cells and ameliorated graft pathological changes. rhIL-37 displayed significantly less splenic populations of Th1 and Th17 cells, as well as matured dendritic cells. The percentages of Tregs in splenocytes were significantly increased in the therapy group. Furthermore, rhIL-37 markedly decreased the levels of TNF-α and IFN-γ, but increased the level of IL-10 in the recipients. In addition, rhIL-37 inhibited the expression of p-mTOR in CD4 cells of splenocytes. In vitro, similar to the in vivo experiments, rhIL-37 caused a decrease in the proportion of Th1 and Th17, as well as an increase in the proportion of Treg and a reduction in p-mTOR expression in CD4 cells.
We demonstrated that rhIL-37 effectively suppress acute rejection and induce long-term allograft acceptance. The results highlight that IL-37 could be novel and promising candidate for prevention of allograft rejection.
同种异体移植排斥仍是长期移植物存活的主要障碍。尽管先前的研究表明,IL-37 在各种疾病中表现出显著的免疫调节作用,但对其在实体器官移植中的作用的研究尚未完全阐明。在这项研究中,评估了重组人 IL-37(rhIL-37)在小鼠心脏同种异体移植模型中的治疗效果。
接受 BALB/c 供体心脏的 C57BL/6 受体小鼠接受 rhIL-37 治疗。术后第 7 天分析移植物病理和免疫组织学变化、免疫细胞群和细胞因子谱。体外评估 Th1、Th17 和 Treg 亚群的增殖能力。此外,还阐明了 rhIL-37 诱导的 CD4 细胞抑制中 p-mTOR 途径的作用。
与未治疗组相比,rhIL-37 治疗实现了长期心脏同种异体移植物存活,并有效缓解了同种异体移植排斥反应,表现为 CD4 和 CD11c 细胞浸润明显减少,移植物病理变化改善。rhIL-37 显示脾细胞中 Th1 和 Th17 细胞以及成熟树突状细胞的数量明显减少。治疗组脾细胞中 Treg 的比例显著增加。此外,rhIL-37 明显降低了受体中 TNF-α 和 IFN-γ 的水平,但增加了 IL-10 的水平。此外,rhIL-37 抑制了脾细胞 CD4 细胞中 p-mTOR 的表达。在体外,与体内实验相似,rhIL-37 导致 Th1 和 Th17 的比例降低,Treg 的比例增加,CD4 细胞中 p-mTOR 的表达减少。
我们证明 rhIL-37 有效抑制急性排斥反应并诱导长期同种异体移植接受。结果表明,IL-37 可能是预防同种异体排斥反应的新型有前途的候选药物。